{
  "id": "fda_guidance_chunk_0278",
  "title": "Introduction - Part 278",
  "text": "foreign regulatory authorities. 5.1.3 Quality control should be applied to each stage of data handling to ensure that all data are reliable and have been processed correctly. Contains Nonbinding Recommendations 5.1.4 Agreements, made by the sponsor with the investigator/institution and any other parties involved with the clinical trial, should be in writing, as part of the protocol or in a separate agreement. 5.2 Contract Research Organization (CRO) 5.2.1 A sponsor may transfer any or all of the sponsor's trial-related duties and functions to a CRO, but the ultimate responsibility for the quality and integrity of the trial data always resides with the sponsor. The CRO should implement quality assurance and quality control. 5.2.2 Any trial-related duty and function that is transferred to and assumed by a CRO should be specified in writing. ADDENDUM The sponsor should ensure oversight of any trial-related duties and functions carried out on its behalf, including trial-related duties and functions that are subcontracted to another party by the sponsor's contracted CRO(s). 5.2.3 Any trial-related duties and functions not specifically transferred to and assumed by a CRO are retained by the sponsor. 5.2.4 All references to a sponsor in this guidance also apply to a CRO to the extent that a CRO has assumed the trial-related duties and functions of a sponsor. 5.3 Medical Expertise The sponsor should designate appropriately qualified medical personnel who will be readily available to advise on trial-related medical questions or problems. If necessary, outside consultant(s) may be appointed for this purpose. 5.4 Trial Design 5.4.1 The sponsor should utilize qualified individuals (e.g., biostatisticians, clinical pharmacologists, and physicians) as appropriate, throughout all stages of the trial process, from designing the protocol and CRFs and planning the analyses to analyzing and preparing interim and final clinical trial reports. 5.4.2 For further guidance: Clinical Trial Protocol and Protocol Amendment(s) (see section 6), the ICH Guideline for Structure and Content of Clinical Study Reports, and other appropriate ICH guidance on trial design, protocol, and conduct. Contains Nonbinding Recommendations 5.5 Trial Management, Data Handling, and Recordkeeping 5.5.1 The sponsor should utilize appropriately qualified individuals to supervise the overall conduct of the trial, to handle the data, to verify the data, to conduct the statistical analyses, and to prepare the trial reports. 5.5.2 The sponsor may consider establishing an independent data monitoring",
  "source": "FDA_clinical_trial_guidance.txt",
  "section_heading": "Introduction",
  "start_pos": 372288,
  "end_pos": 373824,
  "tokens": 512,
  "tags": [
    "design",
    "statistical",
    "regulatory",
    "clinical_trial",
    "data"
  ],
  "jurisdiction": "US",
  "document_type": "fda_guidance",
  "guidance_section": "general_guidance",
  "regulatory_weight": "recommendation",
  "created_at": "2025-10-23T02:25:44.697Z"
}